| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | 5T4 |
| Uniprot No | Q13641 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 60-345aa |
| 氨基酸序列 | DQCPALCECS EAARTVKCVN RNLTEVPTDL PAYVRNLFLT GNQLAVLPAG AFARRPPLAE LAALNLSGSR LDEVRAGAFE HLPSLRQLDL SHNPLADLSP FAFSGSNASV SAPSPLVELI LNHIVPPEDE RQNRSFEGMV VAALLAGRAL QGLRRLELAS NHFLYLPRDV LAQLPSLRHL DLSNNSLVSL TYVSFRNLTH LESLHLEDNA LKVLHNGTLA ELQGLPHIRV FLDNNPWVCD CHMADMVTWL KETEVVQGKD RLTCAYPEKM RNRVLLELNS ADLDCD |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于5T4重组蛋白的3篇代表性文献摘要整理：
---
1. **文献名称**：*Expression of 5T4 oncofetal antigen in human colorectal carcinoma: Association with patient prognosis*
**作者**：Starzynska T, et al.
**摘要**：该研究分析了结直肠癌患者中5T4抗原的表达水平，发现其高表达与肿瘤分期、转移风险增加及预后不良显著相关。研究通过重组5T4蛋白制备抗体，验证了其作为预后标志物的潜力。
---
2. **文献名称**：*A phase I trial of a recombinant 5T4 protein vaccine (TroVax) in advanced prostate cancer*
**作者**：Amato RJ, et al.
**摘要**：该临床试验评估了基于重组5T4蛋白的疫苗TroVax在晚期前列腺癌患者中的安全性和免疫原性。结果显示，疫苗可诱导特异性T细胞反应，且耐受性良好，支持其进一步用于癌症免疫治疗研究。
---
3. **文献名称**：*5T4 interacts with TIP-2/GIPC in the regulation of Wnt signaling and cell migration*
**作者**：Carsberg CJ, et al.
**摘要**：研究利用重组5T4蛋白探讨其与TIP-2/GIPC蛋白的相互作用，揭示了5T4通过调控Wnt信号通路影响肿瘤细胞迁移的分子机制，为靶向5T4的抗转移疗法提供理论依据。
---
以上文献分别从临床预后、免疫治疗和分子机制角度探讨了5T4重组蛋白的应用与功能，覆盖了基础研究与转化医学领域。
The 5T4 recombinant protein, derived from the human trophoblast glycoprotein (TPBG) encoded by the *TPBG* gene, is a transmembrane glycoprotein initially identified in placental trophoblasts. Structurally, it features leucine-rich repeats and a heavily glycosylated extracellular domain, facilitating interactions with extracellular matrix components and cellular signaling pathways. Notably, 5T4 is minimally expressed in healthy adult tissues but overexpressed in diverse carcinomas, including colorectal, ovarian, gastric, and non-small cell lung cancers. This tumor-selective expression pattern, coupled with its role in promoting epithelial-mesenchymal transition (EMT), metastasis, and immune evasion, positions 5T4 as a compelling therapeutic target.
Recombinant 5T4 proteins are typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to preserve native glycosylation and conformational epitopes critical for antibody recognition. These proteins serve as essential tools for functional studies, diagnostic assays, and vaccine development. Preclinical studies highlight 5T4's involvement in Wnt/β-catenin and Hippo signaling pathways, modulating cell adhesion, migration, and stemness. Clinically, 5T4-targeted immunotherapies—such as antibody-drug conjugates, CAR-T cells, and viral vector-based vaccines—have entered trials, leveraging recombinant 5T4 antigens for preclinical validation and immune response monitoring.
Despite challenges like tumor heterogeneity and on-target/off-tumor toxicity risks, 5T4 remains a priority in oncology research due to its prognostic value and potential synergy with checkpoint inhibitors. Recombinant 5T4 proteins continue to underpin mechanistic insights and translational applications in cancer immunotherapy.
×
